恶性血液病患者血小板输注无效与淋巴细胞毒试验同种免疫的关系  

The relationship between ineffective platelet transfusion and LCT in hematologic malignancy

作　　者：邹小立[1] 陈澍英[1] 黄梓伦[1] 肖露露[2] 叶欣[2] 林伟[1] 佘妙容[1] 谢蓉[1] 吴穗晶[1] 

机构地区：[1]广东省人民医院,广州510080 [2]广州器官移植配型中心

出　　处：《中国实用内科杂志》2004年第9期529-530,共2页Chinese Journal of Practical Internal Medicine

基　　金：广东省科委重点攻关项目 (编号 :1997-114 -19);广东省人民医院科研基金资助项目 (编号 :2 0 0 0Y10)

摘　　要：目的　探讨恶性血液病患者血小板输注无效与淋巴细胞毒试验 (LCT)同种免疫的关系。方法　对1997- 12～ 2 0 0 2 - 12广东省人民医院 5 9例恶性血液病患者经多次血小板输注后进行淋巴细胞毒试验 ,进行血小板校正增加值测定 (CCI) ,探讨LCT与血小板输注无效之间的关系。结果　患者中 ,LCT阳性率 38 6 % ;其中 ,急性淋巴细胞白血病 (ALL)LCT阳性率 4 6 1% ;急性非淋巴细胞白血病 (AML)LCT阳性率 34 8% ;ALL与AML之间LCT阳性率差异无显著性意义 (χ2 =0 4 5 2 ,P >0 0 5 )。CCI无效组 32 2 % ,其中LCT阳性者 5 7 9% ;CCI有效组 6 7 8% ,其中LCT阳性者 12 5 %。CCI无效组与CCI有效组LCT阳性率差异有显著性 (χ2 =13 4 3,P <0 0 1)。结论　发现大多数患者LCT滴度越高 ,发生血小板输注无效的可能性就越大。Objective To explore the relationship between platelet transfusion and LCT in hematologic malignancy patients.Methods The relationship between the corrected count increment (CCI) of platelet and lymphocytotoxicity (LCT) and ineffective platelet transfusion were determinated in 59 patients.Results In 59 patients,positive LCT was 38.6%,in which ALL 16.7%,AML 34.8%;there is no significant difference between ALL and AML(χ 2=0.452,P>0.05).In the ineffective group,CCI was 32.2%,in which positive LCT was 57.9%.In the effective group,CCI was 67.8%,in which positive LCT was 12.5%,and there was significant difference in LCT positive rate between the ineffective and effective groups (χ 2=13.43,P< 0.01).Conclusion In this group,the higher the LCT titer,the more likely the ineffective platelet transfusion.

关 键 词：恶性血液病 血小板输注 淋巴细胞毒试验 同种免疫 输注无效 

分 类 号：R552[医药卫生—血液循环系统疾病] R457.1[医药卫生—内科学]